Berupipam
Berupipam is a selective dopamine D1 receptor antagonist of the benzazepine group which was under development for the treatment of psychotic disorders but was never marketed. It reached Phases of [clinical research#Phase I|phase 1] clinical trials prior to the discontinuation of its development.
Berupipam and closely related dopamine D1 receptor antagonists were reported to have been generally well-tolerated in clinical trials, but side effects included restlessness, drowsiness, other central nervous system-related symptoms, and orthostatic hypotension.
Berupipam, in radiolabeled form, has been studied for use in positron emission tomography imaging. The drug was first described in the scientific literature by 1994.